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ABSTRACT
Introduction: Adjunctive mealtime use of the
amylin analog pramlintide improves postprandial
hyperglycemia in patients with type 1 diabetes.
This post hoc analysis of three randomized trials
evaluated whether disease duration affected
responses to pramlintide.
Methods: Patients received mealtime
pramlintide 30 or 60 lg (n = 714) or placebo
(n = 537) as an adjunct to insulin and were
stratified into tertiles by diabetes duration at
baseline. Efficacy and safety end points were
assessed at week 26 using analysis of covariance
and logistic regression models.
Results: Disease durations for tertiles 1, 2, and
3 were 6.7, 16.5, and 29.9 years, respectively. In
all tertiles, pramlintide resulted in greater
reductions in glycated hemoglobin (HbA1c)
and weight than placebo, with greater weight
reductions and insulin sparing in tertiles 2 and
3. Insulin dose and weight increased in the
placebo group in all tertiles. Baseline HbA1c was
a predictor of HbA1c lowering in both
treatment groups (P\0.0001); higher daily
insulin predicted a smaller percent increase in
insulin dose for placebo (P = 0.01); and higher
body weight predicted greater weight loss in
both pramlintide- and placebo-treated patients
(P\0.05). Event rates for severe hypoglycemia
were similar for pramlintide and placebo and
increased with longer duration of diabetes for
both groups. Nausea with pramlintide increased
with longer disease duration.
Conclusion: Mealtime pramlintide resulted in
greater reductions in HbA1c than placebo,
regardless of diabetes duration at baseline.
Longer disease duration appeared to augment
insulin sparing and weight loss with
pramlintide, with a potential for increased
incidence of hypoglycemia and nausea.
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INTRODUCTION
Achieving near-euglycemic levels is the
ultimate goal of treatment for type 1 diabetes.
Because b-cell mass and insulin secretory
capacity are greatly reduced at the time of
clinical onset [1, 2], exogenous insulin therapy
has been the mainstay therapy since its first
introduction in 1922. Basal-bolus insulin
regimens are designed to replicate physiologic
insulin secretion, and new technologies such as
subcutaneous infusion pumps and analog
insulin have helped optimize insulin delivery
in the management of type 1 diabetes.
However, despite these advances, most
patients with type 1 diabetes are unable to
achieve near-normoglycemia [3–5]. This is
mainly because of the difficulty in fully
replicating physiologic insulin delivery and
the increased risks of severe hypoglycemia and
weight gain that are associated with efforts to
intensify therapy [4, 6].
The companion b-cell hormone amylin is
essentially absent in type 1 diabetes [7]. Amylin
deficiency may be a contributor to the clinical
features of type 1 diabetes, and thus
augmentation of amylin may serve clinical
benefit. Amylin functions by regulating
glucose appearance into circulation at the time
of eating by slowing the rate of gastric
emptying, suppressing postprandial glucagon
secretion, and decreasing food intake [8–10].
Thereby, amylin regulates glucose influx into
circulation and its actions are, therefore,
complementary to insulin, which mainly
regulates glucose efflux from circulation
through uptake into glucose storage sites [11].
Native human amylin is not a
suitable pharmaceutical because of its
physiochemical properties, which include poor
solubility and self-aggregation [12, 13]. By
substituting three amino acid residues of
amylin, pramlintide acetate, a soluble,
non-aggregating amylin analog, was developed
for use in humans and replicates the actions of
the naturally occurring hormone amylin—
correcting postprandial hyperglucagonemia,
slowing the rate of gastric emptying, and
improving postprandial glucose excursions [11,
12, 14–19]. Clinical studies have shown that
mealtime use of pramlintide as an adjunct to
insulin for type 1 diabetes resulted in a lowering
of overall glycemia, reduction in postprandial
glucose excursions, sparing of mealtime insulin
use, and overall weight loss [20].
Type 1 diabetes is not a static disease, neither
in terms of the population affected nor within a
given individual. Regarding the former, much
like the general population, patients with type 1
diabetes have become more overweight and
obese over the last 10–20 years, so control of
body weight and accompanying insulin
resistance have become significant
considerations in the management of many
patients [21]. This has directed more attention
to interventions that may help regulate body
weight. Meanwhile, for a given individual, as
the disease progresses over time, a number of
changes occur: (1) early on (generally within
2 years), any residual b-cell secretory capacity
becomes further compromised, limiting any
vestige of insulin and amylin secretion; (2)
individuals tend to gain body weight as they
age, affecting background insulin sensitivity
and thereby exogenous insulin requirements;
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and (3) the defense mechanisms that protect
against hypoglycemia become more
compromised, rendering patients more prone
to this complication [22–28]. Taken together,
the purpose of this retrospective, post hoc
analysis was to evaluate the relationship
between the duration of diabetes and response
to pramlintide treatment (e.g., reduction in
glycated hemoglobin [HbA1c], weight changes,
and risk of hypoglycemia) among patients with
type 1 diabetes in a sizeable cohort drawn from
a controlled clinical trial setting. Baseline
predictors of response were also investigated in
this large pooled population.
METHODS
Study Design
This post hoc analysis included data pooled from
the intent-to-treat (ITT) population from three
pivotal, randomized, placebo-controlled blinded
trials in patients with type 1 diabetes, in which
mealtime pramlintide or placebo was added to
existing insulin regimens, and patients were
instructed not to change their insulin regimen
or diet and exercise program [20, 29, 30]. The
complete methods have been previously
published for two of the studies [20, 30]; the
third study has been presented in abstract form
[29]. The methods of all three studies were
similar and are briefly described herein.
During a lead-in period, patients were treated
with their usual insulin regimen and placebo
administered with the three major meals and a
bedtime snack. In the first study, patients were
randomized to receive pramlintide 30 lg four
times daily (QID) or placebo in addition to their
existing insulin therapy. At week 20, patients in
the pramlintide group whose HbA1c values
decreased by \1% from baseline to week 13
were re-randomized to either pramlintide 30 or
60 lg QID, and those with a C1% decrease
continued with pramlintide 30 lg QID for the
remainder of the study [30]. In the second study,
patients were randomized after the lead-in
period to receive their usual insulin regimen
plus either pramlintide 60 lg three times daily
(TID) or 60 lg QID or placebo QID [20]. In the
third study, patients were randomized after the
lead-in period to receive insulin plus either
pramlintide 60 lg TID or placebo [29]. Study
medication was to be self-administered within
15 min before meals. All studies were conducted
in accordance with the Declaration of Helsinki,
and the ethics committee for each site approved
the protocol. All patients provided written
informed consent prior to study entry.
Patients
Male and female patients aged C16 years with
type 1 diabetes were eligible for enrollment.
Patients had to have a C-peptide level
B0.3 nmol/L, documented history of diabetic
ketoacidosis consistent with type 1 diabetes, or
previously documented islet cell immunemarker
positivity (islet cell antibody or other antibodies
to islet antigens). Patients were treated with
insulin and had an HbA1c value of either 7–13%
[30] or C8% [20, 29] at the time of the screening
visit. Patients were excluded if they had any
severe hypoglycemic or hyperglycemic
symptoms within the last 2 weeks before
screening. Patients were also excluded if they
had any clinically significant disorders of the
cardiovascular, pulmonary, central nervous,
gastrointestinal, renal, or hematological
systems, as well as eating disorders, acute
febrile illness, alcohol/drug abuse, or use of
medications that affect gastrointestinal motility
or glucose/insulin metabolism.
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Analysis of Outcomes
For this post hoc analysis, data for both
treatment groups were pooled and patients
were divided into tertiles by duration of
diabetes at baseline and by placebo and
treatment designation. This allowed for
comparison between pramlintide and placebo
groups within each tertile without adding
treatment as a confounder. Key study end
points were assessed by tertile at week 26,
comparing pramlintide and placebo. Efficacy
end points included change from baseline in
HbA1c, change in body weight, change in total
daily insulin dose, and percent change in total
daily insulin dose at week 26. Safety outcomes
included adverse events (AEs), the rate of severe
hypoglycemia, and the exposure-adjusted
incidence rates of severe hypoglycemia. With
regard to AEs, the coded term anorexia
encompassed verbatims such as decreased
overall appetite, early satiety, and fullness in
two of the studies. Severe hypoglycemia was
defined as an event requiring the assistance of a
third party.
Statistics
The ITT population was used for all analyses.
Missing values at week 26 were imputed using
the last observation carried forward method.
Descriptive statistics were provided for the
baseline information. Means and standard
errors (SEs) of changes in HbA1c, body weight,
and the total daily insulin doses were calculated
for each treatment within each duration of
diabetes tertile. Common AEs and severe
hypoglycemia (exposure-adjusted event rates)
were summarized by duration of diabetes tertile.
Locally weighted scatterplot smoothing
(LOWESS) was used to describe trends related
to changes from baseline in certain end points
of interest in relation to baseline characteristics
and length of disease. Analysis of covariance
(ANCOVA) models were used to investigate
changes in HbA1c, body weight, total daily
insulin dose, and percentage of total daily
insulin dose from baseline as a function of
baseline characteristics and/or duration of
diabetes (i.e., both individual factor effects and
potential interaction effects between baseline
characteristics and duration of diabetes).
Interactions between baseline values and
treatment groups were also explored. P values
were obtained from ANCOVA models. Logistic
regression models were used to explore the
relationship between risk of severe
hypoglycemia versus baseline HbA1c or
duration of diabetes for each pooled treatment
group. Statistical analyses were performed using




A total of 1251 patients were included:
pramlintide 30 or 60 lg (n = 714) or placebo
(n = 537). Regarding the background insulin
regimens, most patients were on multiple
daily injections (59%) or 1–2 injections (30%)
per day. The mean durations of diabetes in
tertiles 1, 2, and 3 were 6.7, 16.5, and 29.9 years,
respectively. Table 1 shows the baseline
characteristics of the population delineated by
tertile. Overall, baseline characteristics appeared
generally similar among all groups. Patients
with longer durations of diabetes (i.e., tertile 3)
for both pramlintide and placebo were slightly
older than those with shorter durations. The
mean daily insulin dose in tertile 2 of the
pramlintide-treated patients was slightly higher
than that in tertiles 1 and 3.
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Outcome Measures
Regardless of duration of diabetes tertile,
patients who received pramlintide experienced
greater reductions in HbA1c compared with
those receiving placebo (Fig. 1a). Moreover,
patients who received pramlintide lost weight,
whereas those who received placebo gained
weight, across all durations of diabetes tertiles
(Fig. 1b). The magnitude of weight loss
appeared to increase with longer diabetes
duration. Insulin dose decreased in the
pramlintide group in tertiles 2 and 3, while it
increased with placebo in all three tertiles
(Fig. 1c).
On the basis of the tertile data, HbA1c and
weight change were assessed for their
relationship with the corresponding baseline
characteristics and duration of diabetes. The
LOWESS plots for both the pramlintide and
placebo groups suggested that baseline HbA1c,
but not duration of diabetes, was predictive of
change in HbA1c at end point (Fig. 2). This was
further confirmed by modeling change in
HbA1c versus baseline HbA1c and duration of
diabetes through ANCOVA models. Baseline
HbA1c was a significant factor for change in
HbA1c for pramlintide [parameter estimate
(SE) = -0.2818 (0.0347); P\0.0001] and
placebo [parameter estimate (SE) = -0.2742
(0.0380); P\0.0001]. Duration of diabetes was
not a significant factor for change in HbA1c in
either treatment group. Baseline daily insulin
dose and duration of diabetes were not
Table 1 Baseline characteristics of the population at screening by tertile group (intent-to-treat population)













Male, n (%) 116 (52.0) 128 (52.7) 123 (49.6) 99 (51.6) 96 (54.5) 94 (55.6)
Age, years, mean (SD) 36.6 (12.6) 39.2 (12.4) 44.0 (10.9) 37.4 (13.0) 37.5 (11.8) 46.3 (11.6)
Race, n (%)
Asian 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 2 (1.1) 0 (0.0)
Black 4 (1.8) 3 (1.2) 5 (2.0) 5 (2.6) 4 (2.3) 3 (1.8)
White 209 (93.7) 229 (94.2) 236 (95.2) 177 (92.2) 162 (92.0) 163 (96.4)
Hispanic 8 (3.6) 10 (4.1) 5 (2.0) 9 (4.7) 5 (2.8) 3 (1.8)
Other 2 (0.9) 1 (0.4) 1 (0.4) 1 (0.5) 3 (1.7) 0 (0.0)
Weight, kg, mean (SD) 76.6 (13.9) 77.0 (14.3) 74.4 (14.4) 72.9 (12.9) 76.7 (14.8) 76.3 (14.8)
BMI, kg/m2, mean (SD) 25.6 (3.8) 26.2 (3.9) 25.9 (4.4) 25.1 (3.7) 26.1 (4.3) 26.2 (4.4)
HbA1c, %, mean (SD) 9.0 (1.3) 8.9 (1.2) 8.8 (1.1) 9.2 (1.4) 9.0 (1.3) 8.6 (1.0)
Total daily insulin dose,
U, mean (SD)
51.3 (23.7) 57.3 (44.7) 45.5 (26.3) 47.8 (20.5) 53.3 (25.4) 49.5 (54.9)
Duration of diabetes,
years, mean (SD)
6.6 (3.0) 16.4 (2.8) 29.5 (6.5) 6.8 (2.7) 16.5 (3.1) 30.2 (7.1)
BMI body mass index, HbA1c glycated hemoglobin, SD standard deviation, U units
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Fig. 1 Mean ± standard error changes from baseline in a HbA1c, b body weight, and c insulin dose at 26 weeks
(intent-to-treat population). HbA1c glycated hemoglobin, T tertile
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significant factors for percent change in daily
insulin dose at end point in the pramlintide
group. In the placebo group, duration of
diabetes was not a significant factor for
percent change in insulin dose, whereas
baseline insulin dose was inversely related to
percent change in insulin dose [parameter
estimate (SE) = -0.2918 (0.1156); P = 0.0120].
Thus, a higher baseline insulin dose was
associated with a smaller percent increase in
insulin dose. The LOWESS plots for the
pramlintide and placebo groups suggested that
baseline weight, but not duration of diabetes,
was potentially predictive of change in weight
at end point (Fig. 3). The ANCOVA models
confirmed that baseline weight alone was a
marginally significant predictor of weight
change at end point in the pramlintide
[parameter estimate (SE) = -0.0194 (0.0088);
P = 0.0276] and placebo [parameter estimate
(SE) = -0.0196 (0.0096); P = 0.0420] groups.
The interactions between corresponding
baseline values and duration of diabetes were
also explored in these ANCOVA models, and
their effects were not significant (data not
shown).
Adverse Events
The observed AEs with pramlintide were
consistent with those observed in previous
publications [20, 29, 30]. The most common
AEs among pramlintide-treated patients were
nausea (45.4%) and hypoglycemia (21.6%),
with risk increasing with longer duration of
diabetes (Table 2). Nausea occurred more
frequently in patients treated with pramlintide
compared with those receiving placebo; in each
tertile, rates of nausea with pramlintide were
approximately threefold greater than with
placebo. Anorexia, which included a reduction
Fig. 2 Relationship between baseline HbA1c with change
in HbA1c at end point in the a pramlintide and b placebo
treatment groups. Relationship between baseline duration
of diabetes with change in HbA1c at end point in the
c pramlintide and d placebo treatment groups. HbA1c
glycated hemoglobin
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in appetite, a known mechanism of action of
pramlintide, occurred in a greater percentage of
pramlintide-treated patients than placebo
recipients and increased with longer duration
of diabetes in the pramlintide group but not in
the placebo group. In the pramlintide group,
the incidence of headache decreased with
increasing duration of diabetes, while the
incidence increased in the placebo group.
Trends in relation to duration of diabetes were
generally not observed for the other AEs in
either group.
The incidence of severe hypoglycemia was
higher with pramlintide compared with
placebo (Table 2). Patients may have had
more than one event of hypoglycemia, and
therefore the exposure-adjusted event rate was
calculated to more appropriately reflect the
burden of disease and its management. The
exposure-adjusted event rates per patient-year
of severe hypoglycemia for pramlintide and
placebo were generally similar (Table 2).
Logistic regression analysis showed that in
the pramlintide group, longer duration of
disease was associated with a marginally
significantly higher risk of severe
hypoglycemia [odds ratio (OR), 1.04; 95%
confidence interval (CI), 1.03–1.06], and
higher baseline HbA1c was associated with a
lower risk of severe hypoglycemia (OR, 0.75;
95% CI, 0.65–0.87). For the placebo group, a
longer duration of diabetes was also associated
with a marginally significantly higher risk of
severe hypoglycemia (OR, 1.04; 95% CI,
1.01–1.06). The interactions between baseline
values and duration of diabetes were also
explored in the logistic regression analysis for
severe hypoglycemia and were found to be
nonsignificant for each treatment group (data
not shown).
Fig. 3 Relationship between baseline weight with change
in weight at end point in the a pramlintide and b placebo
treatment groups. Relationship between baseline duration
of diabetes with change in weight at end point in the
c pramlintide and d placebo treatment groups
Adv Ther (2016) 33:848–861 855
DISCUSSION
Because patients with type 1 diabetes require
lifelong therapy and experience further
deterioration of residual b-cell function,
weight gain, and an increased risk of
hypoglycemia over time after diagnosis, it is
important to evaluate the effectiveness of
treatment in patients across a spectrum of
diabetes disease duration. This post hoc
analysis demonstrated that mealtime
pramlintide added to insulin was effective
in reducing HbA1c levels and body weight
across a wide range of disease durations, from
early after diagnosis to beyond 40 years.
Pramlintide-treated patients who had had type
1 diabetes for longer appeared to demonstrate a
greater reduction in body weight coupled with a
greater insulin-sparing effect; however, disease
duration alone was not confirmed to be a
significant determinant of pramlintide
responsiveness. Baseline HbA1c and baseline
weight were observed to be more influential
predictors of change in HbA1c and weight,
respectively, in both the pramlintide and
placebo treatment groups. Baseline daily
insulin dose was a predictor for percent
change in insulin dose for the placebo group
only, with higher baseline insulin dose
predicting a smaller percent increase in insulin
dose. By the nature of the current analysis and
the difficult confounding interrelationships
that exist among glycemic and body control
mechanisms and insulin dosing, it is unclear
whether the observations regarding weight loss
and insulin are in some way interrelated. One
could speculate the following scenarios as
examples: (1) a greater pramlintide-induced
weight loss resulted in a greater reduction in
insulin requirements, or (2) a more profound
glycemic effect resulted in greater insulin
sparing (that may have offset overall chronic
measures) and this, in turn, had a downstream
effect on body weight. The dataset and the
analysis employed in this paper did not have
the capability to fully discern these complex
interrelationships but can inform future
analytical work.
Also noted in the present analysis,
pramlintide was associated with weight loss
versus the weight gain seen with insulin alone
[20, 29–31]. However, it is well recognized
that insulin, especially the intensified use of
mealtime insulin, is associated with weight
gain to the extent that it becomes a major
disincentive for patients to attempt to
optimize glycemic control [32–34]. Moreover,
insulin-induced weight gain in patients with
type 1 diabetes has been shown to have
detrimental downstream effects on
cardiovascular risk factors, including blood
pressure and circulating lipids [35, 36].
Therefore, therapies that mitigate the risk of
weight gain without negatively affecting
glycemic control are of special interest, and
the role of glucagon-like peptide-1 and amylin
receptor agonists are key in this regard.
In the current analysis, a higher incidence
(but similar exposure-adjusted event rate) of
severe hypoglycemia was observed with
pramlintide versus placebo. In both groups, a
longer duration of diabetes was associated with
a higher risk of hypoglycemia. This is consistent
with other studies of patients with type 1
diabetes where a trend toward increased
hypoglycemia risk is observed with advancing
disease duration. A retrospective review of 7012
patient records showed a strong correlation
between diabetes duration and severe
hypoglycemia (P\0.001) that was not
attributable to any increase in age [37]. This
phenomenon has been ascribed to the stepwise
erosion of counter-regulatory defense
mechanisms that occurs over time: the early
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loss of b-cell function and therefore its paracrine
relationship with the a cell, an almost absent
plasma glucagon response to hypoglycemia
within 2–5 years post-diagnosis, and a later
attenuation of sympathoadrenal responses
[37–39].
The mechanisms whereby pramlintide use
may be related to the occurrence of
hypoglycemia have been previously discussed.
Amiel et al. [40] clearly showed that, in a
series of insulin-infusion hypoglycemic
challenge studies, pramlintide exhibited no
innate hypoglycemic potential and did not
influence counter-regulatory hormonal,
metabolic, or symptomatic responses.
Hypoglycemic clamp studies confirmed much
of the same [41]. Nevertheless, subsequent
placebo-controlled clinical trial work showed
that pramlintide was associated with an
increase in severe hypoglycemia, especially in
the early phase (first few weeks) of study [14,
42–44]. However, the actions elicited by
pramlintide, namely delayed gastric
emptying, reduced food intake, and
postprandial glucose reduction, coupled with
a blinded clinical trial design and active
discouragement of any insulin titration by
investigators and patients, were an obvious
recipe for increased risk of hypoglycemia.
Subsequent clinical trials where appropriate
insulin titration was allowed, which
accommodated the glycemic and appetite
effects of pramlintide, greatly reduced the
accompanying hypoglycemia risk [14, 45].
It should be noted that the post hoc nature
of this analysis limited the strength of
comparisons between and within tertiles, and
therefore the results should be considered
exploratory. Because the protocols for the
three studies reported herein specified that
insulin doses were supposed to be maintained,
it is possible that the changes in insulin dose
Table 2 Adverse events occurring in C10% of patients in any group and rates of severe hypoglycemia (intent-to-treat
population)













Anorexia 13 (5.8) 18 (7.4) 27 (10.9) 3 (1.6) 2 (1.1) 1 (0.6)
Diarrhea 21 (9.4) 15 (6.2) 22 (8.9) 19 (9.9) 24 (13.6) 17 (10.1)
Headache 36 (16.1) 25 (10.3) 24 (9.7) 26 (13.5) 29 (16.5) 29 (17.2)
Inﬂuenza 16 (7.2) 21 (8.6) 13 (5.2) 20 (10.4) 18 (10.2) 25 (14.8)
Nasopharyngitis 23 (10.3) 39 (16.0) 25 (10.1) 29 (15.1) 21 (11.9) 28 (16.6)
Nausea 78 (35.0) 114 (46.9) 132 (53.2) 26 (13.5) 30 (17.0) 26 (15.4)
Upper respiratory tract
infection
19 (8.5) 32 (13.2) 29 (11.7) 18 (9.4) 27 (15.3) 32 (18.9)
Vomiting 14 (6.3) 25 (10.3) 29 (11.7) 10 (5.2) 14 (8.0) 7 (4.1)
Severe hypoglycemia, % 13.5 21.8 27.4 9.4 15.3 21.9
Severe hypoglycemia, event
rate/patient-year
0.5 1.2 1.8 0.6 0.9 2.3
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observed in this study may not be indicative of
what is observed in clinical practice, which may
have had an effect on outcomes, particularly
the risk of hypoglycemia. Indeed, in two
subsequent trials—a dose-titration trial and a
clinical practice trial—in which patients were
encouraged to adjust their insulin dose based on
blood glucose measurements, the reduction in
mealtime insulin was between 20% and 30%
[14, 46]. Comorbidities, which increase over
time and, therefore, may have differed between
tertiles, were also not explored as factors in this
analysis.
CONCLUSIONS
Type 1 diabetes is a lifelong disease, and
treatment must provide reasonable solutions
for sustainable efficacy without an
unmanageable tolerability and safety profile.
The Diabetes Control and Complications Trial
(DCCT; ClinicalTrials.gov identifier: NCT003
60815) and the Epidemiology of Diabetes
Interventions and Complications (EDIC;
ClinicalTrials.gov identifier: NCT00360893)
trial have clearly shown that efforts to
improve glycemia pay dividends regarding
mitigation of later risk of microvascular and
macrovascular complications [47]. Technical
advances in delivering insulin and protecting
against hypoglycemia over the last two decades
have benefited many patients. Alternate
adjunctive approaches that target glycemia
and broader aspects of glucose and weight
control are also attractive in this population.
This analysis highlights the beneficial effects of
pramlintide seen across a wide range of disease
durations, including patients with longer
disease duration. The information derived
from this analysis may assist clinicians in
making long-term treatment decisions for their
patients who have optimized the use of insulin
but have still not reached goal.
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